Recipharm, the contract development and manufacturing organization (CDMO), has entered into a long-term agreement with Sato Pharmaceutical for the commercial manufacture and delivery of Emla Patch to Japanese market.
The Emla Patch is used as a local anaesthetic product and will be launched under the business area of ethical pharmaceuticals at Sato. Recipharm’s facility in Karlskoga, Sweden, will produce and deliver to Sato. It is expected that after a successful launch in Japan the annual volumes of this product will be a significant addition to the present production of the Karlskoga facility.
“We first established a business relationship with Sato in 2012 and this new supply agreement extends our partnership further,” said Ingela Palmkvist, general manager at Recipharm Karlskoga facility. “We are looking forward to the launch in Japan and cooperating with Sato in developing the business, to the benefit of both companies.”